The Tisch Cancer Institute (TCI) Human Immune Monitoring Core Shared Resource Facility (HIMCSRF) provides TCI members access to a comprehensive suite of immune monitoring assays allowing for the quantification of circulating proteins and immune cell characterization, along with spatial organization in tissues to support basic science, clinical, and translational studies. This is achieved by balancing innovation with robust protocols and operating procedures to ensure data quality and reproducibility with dedicated platforms for biospecimen processing and sample management, soluble factor profiling, phenotypic and functional immune cell characterization, immunogenomics, single cell transcriptomics, and multiplexed tissue imaging. The HIMCSRF is comprised of over twenty full time experts who specialize in characterizing immune profiles and responses across a diverse range of disease settings. The HIMC currently supports over 45 federal and foundation funded projects across a diverse range of clinical areas including cancer, and also serves as a central analysis hub for several multi-institutional consortia including the NIH Human Immunology Project Consortium (HIPC). The HIMCSRF is also an NCI-designated Cancer Immune Monitoring and Analysis Center (CIMAC) as part of a U24 consortium funded through the Cancer Moonshot program, and also actively supports 13 industry-sponsored research collaborations. Since its inception in 2011, the HIMCSRF contributed to the TCI?s mission by providing state-of-the-art technologies, project development, consistency, interpretations, and cost-effectiveness to all TCI programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022661
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Galsky, Matthew D; Wang, Huan; Hahn, Noah M et al. (2018) Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol 73:751-759
Tsuchida, Takuma; Lee, Youngmin A; Fujiwara, Naoto et al. (2018) A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69:385-395
Molotkov, Andrei; Soriano, Philippe (2018) Distinct mechanisms for PDGF and FGF signaling in primitive endoderm development. Dev Biol 442:155-161
Wu, Vernon; Moshier, Erin; Leng, Siyang et al. (2018) Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2:1470-1479
Parua, Pabitra K; Booth, Gregory T; Sansó, Miriam et al. (2018) A Cdk9-PP1 switch regulates the elongation-termination transition of RNA polymerase II. Nature 558:460-464
Zhang, Yan M; Zimmer, Milena A; Guardia, Talia et al. (2018) Distant Insulin Signaling Regulates Vertebrate Pigmentation through the Sheddase Bace2. Dev Cell 45:580-594.e7
Schwartz, Rebecca M; Gorbenko, Ksenia; Kerath, Samantha M et al. (2018) Thoracic surgeon and patient focus groups on decision-making in early-stage lung cancer surgery. Future Oncol 14:151-163
Lee, Youngmin A; Noon, Luke A; Akat, Kemal M et al. (2018) Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 9:4962
Laganà, A; Perumal, D; Melnekoff, D et al. (2018) Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia 32:120-130
Scarborough, Bethann M; Smith, Cardinale B (2018) Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68:182-196

Showing the most recent 10 out of 143 publications